Table 5.

Prostate-specific antigen slopes before and after vaccine treatment (step 1)

(n = 31)*	Median (log PSA/mo)	IQR (log PSA/mo)	p value**
6-mo PSA data
Pretreatment slope	0.13	(0.08–0.17)	–
During treatment slope	0.09	(0.06–0.12)	–
Difference between pretreatment and during treatment	−0.04	(−0.08 to 0.01)	0.02
3-mo PSA data
Pretreatment slope	0.13	(0.08–0.15)	–
During treatment slope	0.08	(0.04–0.15)	–
Difference between pretreatment and during treatment	−0.03	(−0.08 to 0.04)	0.10

IQR = interquartile range; PSA = prostate-specific antigen.

^*Among 30 patients (one patient was excluded because his 6-mo PSA was measured >3 mo away from the 6-mo time point) included in the PSA velocity analysis, the baseline PSA median was 2.0 (IQR: 1.5–5.4) and the 6-mo PSA median was 4.2 (IQR: 2.4–9.6).

^**Wilcoxon signed rank test.